Search
Paliroden
go.drugbank.com/drugs/DB05454InvestigationalPaliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It...
Synonyms: 1-(2-(Biphenyl-4-yl)ethyl)-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridineBriakinumab
go.drugbank.com/drugs/DB05459InvestigationalBriakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders.
ISS-1018
go.drugbank.com/drugs/DB05463InvestigationalISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. … ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults.
WX-UK1
go.drugbank.com/drugs/DB05476InvestigationalWX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. … Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.
PBI-1402
go.drugbank.com/drugs/DB05480ExperimentalPBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. … PBI-1402 is a small molecule synthetic compound with oral Bioavailability.
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance
KW-7158
go.drugbank.com/drugs/DB05498ExperimentalKW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity … The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion
Categories: Heterocyclic Compounds, 2-RingAVN-944
go.drugbank.com/drugs/DB05500InvestigationalAVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalMavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. … by a reduced number of mature neutrophils and lymphocytes.
Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsSynonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-, N1-(1H-BENZIMIDAZOL-2-YLMETHYL)-N1-((S)-5,6,7,8-TETRAHYDROQUINOLIN-8-YL)-BUTANE-1,4-DIAMINENM-702
go.drugbank.com/drugs/DB05505InvestigationalIntermittent claudication is a major symptom of arteriosclerosis obliterans. … In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed.
Categories: Heterocyclic Compounds, 1-Ring